{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:15:12Z","timestamp":1781846112538,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.seizure.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T19:17:35Z","timestamp":1736277455000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["First clinical post-approval, observational study to assess clinical safety and effectiveness of brivaracetam sustained-release formulation in real-life settings of India: BEAM study"],"prefix":"10.1016","volume":"125","author":[{"given":"Lakshmi Narasimhan","family":"Ranganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-0217","authenticated-orcid":false,"given":"Girish","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5821-418X","authenticated-orcid":false,"given":"Ashutosh","family":"Kakkad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-0230","authenticated-orcid":false,"given":"Krishnaprasad","family":"Korukonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5015-0413","authenticated-orcid":false,"given":"Narendra","family":"Chouksey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.seizure.2025.01.011_bib0001","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.seizure.2025.01.011_bib0002","doi-asserted-by":"crossref","first-page":"e2589","DOI":"10.1002\/brb3.2589","article-title":"The burden of epilepsy and unmet need in people with focal seizures","volume":"12","author":"Ioannou","year":"2022","journal-title":"Brain Behav"},{"issue":"4","key":"10.1016\/j.seizure.2025.01.011_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2025.01.011_bib0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The Epidemiology of Epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.seizure.2025.01.011_bib0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2022.10.009","article-title":"Narrative review of brivaracetam for genetic generalized epilepsies","volume":"103","author":"Lince-Rivera","year":"2022","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.seizure.2025.01.011_bib0006","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40263-023-01033-4","article-title":"Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records","volume":"37","author":"Villanueva","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2025.01.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109922","article-title":"Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies","volume":"158","author":"Faught","year":"2024","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.011_bib0008","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1535-7511.2009.01326.x","article-title":"Extended-release formulations of antiepileptic drugs: rationale and comparative value","volume":"9","author":"Perucca","year":"2009","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2025.01.011_bib0009","unstructured":"Kasu RRR, Das S, Thommandru VK. Controlled release pharmaceutical compositions of brivaracetam. European Patent 2013;2563339(A1)."},{"key":"10.1016\/j.seizure.2025.01.011_bib0010","unstructured":"New Drugs Approval list from SND Division (FROM 01\/0\/\/2023 TO 31\/12\/2023). cdsco.gov.in. Available from: https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=MTExNjg=. Accessed July 17, 2024."},{"issue":"5","key":"10.1016\/j.seizure.2025.01.011_bib0011","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/epi.17223","article-title":"Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures","volume":"63","author":"Lattanzi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.011_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eplepsyres.2015.11.017","article-title":"Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study","volume":"120","author":"Chung","year":"2016","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2025.01.011_bib0013","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40120-022-00402-3","article-title":"Brivaracetam as early add-on treatment in patients with focal seizures: a retrospective, multicenter, real-world study","volume":"11","author":"Lattanzi","year":"2022","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.011_bib0014","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.01.011_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eplepsyres.2016.09.003","article-title":"Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies","volume":"127","author":"Moseley","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.01.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106694","article-title":"Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis","volume":"176","author":"Moseley","year":"2021","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.seizure.2025.01.011_bib0017","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2025.01.011_bib0018","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1111\/epi.17087","article-title":"Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up","volume":"62","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2025.01.011_bib0019","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40263-021-00856-3","article-title":"Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2025.01.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.01.011_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.seizure.2024.02.022","article-title":"Psychiatric assessment prior to and after switch from levetiracetam to brivaracetam","volume":"117","author":"Kassoum","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.01.011_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106433","article-title":"Network meta-analysis of antiepileptic drugs in focal drug-resistant epilepsy","volume":"167","author":"Hu","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.01.011_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123301","article-title":"Design and evaluation of gastro-swelling\/gastro-floating sustained-release tablets of brivaracetam for epilepsy therapy","volume":"644","author":"Hou","year":"2023","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.011_bib0024","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1007\/s00415-024-12253-z","article-title":"Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis","volume":"271","author":"Szaflarski","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.seizure.2025.01.011_bib0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.yebeh.2016.11.031","article-title":"Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis","volume":"69","author":"Brandt","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.011_bib0026","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40801-021-00246-7","article-title":"Brivaracetam Retention Rate and Seizure Outcomes in Patients with Drug-Resistant Focal Epilepsy Included in the Medical Need Program in Belgium: A Real-World, Multicenter, Chart Review","volume":"8","author":"Depondt","year":"2021","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.seizure.2025.01.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106329","article-title":"Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe","volume":"165","author":"Steinhoff","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.01.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106967","article-title":"Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation","volume":"106","author":"Adewusi","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.01.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106694","article-title":"Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis","volume":"176","author":"Moseley","year":"2021","journal-title":"Epilepsy Res"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112500010X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112500010X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T15:09:06Z","timestamp":1769958546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913112500010X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"alternative-id":["S105913112500010X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First clinical post-approval, observational study to assess clinical safety and effectiveness of brivaracetam sustained-release formulation in real-life settings of India: BEAM study","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Torrent Pharmaceuticals Limited. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}